红曲提取物对恶性肿瘤外周血中CD62p及CD63作用的研究进展.pdfVIP

·868 · 医学 综述 20 12 年 3 月第 18 卷 第 6 期 Medical Recapitul ate , Mar. 20 12 , V ol . 18 , No. 6 [ 22] Chanan-Khan A , Wolf JL, Garcia J, et al. Efficacy analysis from ability and promising activity in a heavily pretreated population phase Ⅰ study of lorvotuzumab mertansine ( IMGN901) , used as [ J] . Blood, 20 10 , 116( 2 1) : 1951. monotherapy , in patients with heavily pre-treated CD56 -positive [ 26] Podar K, Raab MS, Z hang J, et al. Targeting PKC in multiple mye- multiple myeloma-a preliminary effi cacy analysis [ J] . Blood, 20 10 , loma: in vitro and in vivo effects of the novel, orally available small- 116( 21) : 1962. molecule inhibitor enzastaurin ( LY3176 15. HCl ) [ J ] . Blood, [ 23] Richardson PG, Chanan-Khan A, Lonial S, et al. Tanespimycin + 2007 , 109 ( 4) : 1669-1677. bortezomib demonstrates safety, activity, and effective target inhibi- [ 27] Kim K, Kong SY, Fulciniti M. Blockade of the MEK / ERK signal- tion in relapsed / refractory myeloma patients: updated results of a ling cascade by A S703026, a novel selective MEK1 /2 inhibitor, in- phase 1 /2 study [ J] . Blood, 2009, 114( 22) : 2890-289 1. duces pleiotropic anti -myeloma activity in vitro and in vivo[ J] . Br [ 24] Badros A, Burger AM, Philip S, et al. Phase Ⅰ study of vorinostat J Haematol, 2010, 149 ( 4) : 537-549 . in combination with bortezomib for rel apsed and refractory multiple [ 28] Cretney E, Takeda K, Smyth MJ. Cancer: novel therapeutic strate- myeloma[ J] . Clin Cancer Res, 2009, 15 ( 16) : 5250-5257. gies that exploit the TNF-related apoptosis inducing ligand [ 25] Richardson P, Weber D, Mitsiades CS, et al. A Phase Ⅰ study of ( TRAIL) / TRAIL receptor pathway [ J] . Int J Biochem Cell Biol, vorinostat, lenalidomi de, and dexa